Replies to post #6916 on AEterna Zentaris Inc. (AEZS)

[alexander77]

Your calculation was inaccurate. You should not take the lowest share price, but the average conversion price.
In my calculations where the warrant holder first exercised 20% of the warrants to be able to manipulate the share price and then steadily exercise the 80% remaining warrants, there would be max 700 million shares outstanding if they convert all 80% at .05 (but as I have said the probably converted between
.10 and .05) More likely it would be 450-600 million shares.

According to the Adam Feuerstein biotech oncology rule, which says an oncology firm should have a market cap of at least $300m after phase 3 results are announced and prior to the FDA final decision, AEZS should have a share price of at least $.50/share at least.